GO:2000077 negative regulation of type B pancreatic cell development: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000077 describes any process that stops, prevents, or reduces the frequency, rate or extent of pancreatic B cell (beta cell) development [1, 2].
• This negative regulation is essential for balancing beta cell mass and maintaining glucose homeostasis; its dysregulation contributes to type 2 diabetes [1, 2].
• Key molecular players include FXR, COX6A2, mTOR, SOCS-3, FoxO1, HIF1α, and tetranectin, which modulate beta cell survival, proliferation, and function [1, 2, 4, 5, 6, 8].
• Excess pancreatic elastase impairs acinar-beta cell communication via PAR2 signaling, indirectly affecting beta cell development and function.
• Lipid droplet accumulation in beta cells is linked to beta cell demise in type 2 diabetes, highlighting metabolic regulation of beta cell fate.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of genes that negatively regulate beta cell development [1, 2, 4, 5, 6, 8].
Description
Pancreatic beta cells are the sole source of insulin in the body, and their proper development is critical for glucose homeostasis. The Gene Ontology term GO:2000077, negative regulation of type B pancreatic cell development, encompasses any process that stops, prevents, or reduces the frequency, rate or extent of beta cell development [1, 2]. This regulatory mechanism is essential for maintaining an appropriate beta cell mass and preventing hyperinsulinemia or beta cell exhaustion. Dysregulation of this process is increasingly recognized as a contributor to type 2 diabetes and other metabolic disorders [1, 2, 7]. Understanding the molecular players that negatively regulate beta cell development can reveal therapeutic targets for preserving or restoring beta cell function. Recent studies have identified several key regulators, including FXR, COX6A2, mTOR, SOCS-3, FoxO1, HIF1α, and tetranectin, which influence beta cell survival, proliferation, and differentiation [1, 2, 4, 5, 6, 8]. This article provides a comprehensive overview of GO:2000077, its mechanisms, associated genes, disease relevance, and research methodologies, with a focus on CRISPR-based approaches for functional validation.
negative regulation of type B pancreatic cell development At A Glance
| GO ID | GO:2000077 |
|---|---|
| GO term | negative regulation of type B pancreatic cell development |
| Ontology | biological_process |
| Synonym | negative regulation of pancreatic B cell development; negative regulation of pancreatic beta cell development |
| Major function | Limits beta cell mass by inhibiting proliferation, inducing apoptosis, or blocking differentiation |
| Related processes | Regulation of beta cell mass, insulin secretion, glucose homeostasis |
| Key regulators | FXR, COX6A2, mTOR, SOCS-3, FoxO1, HIF1α, tetranectin |
| Disease relevance | Type 2 diabetes, beta cell dysfunction, metabolic syndrome |
What Is GO:2000077?
GO:2000077 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of pancreatic B cell development. In simpler terms, it covers the biological brakes that limit the formation, growth, or maturation of insulin-producing beta cells. This negative regulation ensures that beta cell numbers do not exceed physiological needs and that defective or excess cells are eliminated. It includes mechanisms such as inhibition of beta cell proliferation, induction of apoptosis, and blockade of differentiation from progenitor cells [1, 2, 4, 5, 6, 8].
Why Is negative regulation of type B pancreatic cell development Important in Cell Biology?
GO:2000077 is crucial because it governs the delicate balance of beta cell mass, which directly impacts insulin availability and glucose control. Excessive negative regulation can lead to beta cell loss and diabetes, while insufficient negative regulation may contribute to hyperinsulinism. Understanding this process provides insights into diabetes pathogenesis and identifies potential therapeutic targets to protect or regenerate beta cells [1, 2, 4, 5, 6, 8].
• Maintains beta cell mass within physiological limits to prevent hyperinsulinemia or beta cell exhaustion [1, 2].
• Dysregulation contributes to beta cell failure in type 2 diabetes [1, 2, 7].
• Key regulators like FXR and COX6A2 link mitochondrial function and bile acid signaling to beta cell survival.
• mTOR signaling integrates nutrient and growth factor cues to control beta cell proliferation and apoptosis.
• SOCS-3 negatively regulates beta cell proliferation and may mediate cytokine-induced beta cell damage.
• FoxO1 controls juxtaductal endocrine cell formation, affecting beta cell neogenesis.
• HIF1α influences beta cell development under hypoxic conditions.
• Tetranectin, an adipocyte-secreted protein, inhibits insulin secretion and exacerbates diabetes.
• Lipid droplet accumulation in beta cells is linked to beta cell demise, highlighting metabolic stress.
• Excess pancreatic elastase impairs acinar-beta cell communication, indirectly affecting beta cell function.
What Happens During negative regulation of type B pancreatic cell development?
Inhibition of beta cell proliferation
In simple terms: This step slows down or stops beta cells from dividing.
Negative regulation of beta cell development often involves reducing the rate of beta cell proliferation. For example, SOCS-3 has been shown to inhibit beta cell proliferation, thereby limiting beta cell mass expansion. Similarly, mTOR signaling, which promotes proliferation, can be negatively regulated under certain conditions to restrain beta cell growth. This inhibition ensures that beta cell numbers do not exceed metabolic demand.
Induction of beta cell apoptosis
In simple terms: This step causes beta cells to self-destruct.
Apoptosis is a key mechanism for reducing beta cell numbers. FXR-regulated COX6A2 triggers mitochondrial apoptosis of pancreatic beta cells in type 2 diabetes. This pathway involves mitochondrial dysfunction and activation of intrinsic apoptotic cascades, leading to beta cell death and reduced beta cell mass.
Blockade of beta cell differentiation
In simple terms: This step prevents progenitor cells from becoming mature beta cells.
Negative regulation can also occur at the stage of differentiation from endocrine progenitors. FoxO1 regulates the formation of juxtaductal endocrine cells, and its activity can restrict the number of cells committing to the beta cell lineage. HIF1α also influences beta cell development, potentially by modulating differentiation under hypoxic conditions.
Metabolic and signaling interference
In simple terms: This step disrupts the signals that support beta cell health.
Metabolic stress and altered signaling can negatively impact beta cell development. Excess pancreatic elastase impairs acinar-beta cell communication via PAR2 pathways, indirectly affecting beta cell function and survival. Lipid droplet accumulation in beta cells is associated with beta cell demise in type 2 diabetes, indicating that lipid stress contributes to negative regulation. Tetranectin, secreted by adipocytes, inhibits insulin secretion and exacerbates diabetes, further illustrating systemic negative regulation.
Key Genes Involved in GO:2000077 negative regulation of type B pancreatic cell development
The following genes and proteins have been experimentally implicated in the negative regulation of type B pancreatic cell development, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FXR (NR1H4) | Regulates COX6A2 and mitochondrial apoptosis in beta cells | Target for preventing beta cell death in type 2 diabetes |
| COX6A2 | Mitochondrial cytochrome c oxidase subunit; triggers apoptosis | Effector of FXR-mediated beta cell apoptosis |
| mTOR | Kinase regulating beta cell mass and insulin secretion | Central node in beta cell growth and survival signaling |
| SOCS-3 | Cytokine signaling suppressor; inhibits beta cell proliferation | Potential target to enhance beta cell regeneration |
| FoxO1 | Transcription factor controlling endocrine cell formation | Regulates beta cell neogenesis from progenitors |
| HIF1α | Hypoxia-inducible factor; modulates beta cell development | Links oxygen sensing to beta cell differentiation |
| Tetranectin (CLEC3B) | Adipocyte-secreted protein; inhibits insulin secretion | Mediator of obesity-related beta cell dysfunction |
| PAR2 (F2RL1) | Protease-activated receptor; mediates elastase effects | Involved in acinar-beta cell communication |
| Elastase (CELA1) | Pancreatic enzyme; excess impairs beta cell function | Potential link between exocrine and endocrine pancreas |
| Lipid droplets | Storage organelles; accumulation linked to beta cell demise | Marker of metabolic stress in beta cells |
| Insulin (INS) | Hormone produced by beta cells; marker of function | Readout of beta cell development and function [1, 2, 8] |
| PDX1 | Transcription factor essential for beta cell development | Master regulator of beta cell identity |
| Neurogenin3 (NEUROG3) | Proendocrine transcription factor | Required for endocrine lineage commitment |
| MAFA | Transcription factor for beta cell maturation | Marker of functional beta cells |
| NKX6.1 | Transcription factor for beta cell identity | Maintains beta cell phenotype |
| GLUT2 (SLC2A2) | Glucose transporter in beta cells | Facilitates glucose sensing |
| Glucokinase (GCK) | Glucose sensor in beta cells | Rate-limiting step in glucose-stimulated insulin secretion |
| IRS2 | Insulin receptor substrate; mediates growth signals | Links insulin signaling to beta cell survival |
How Is negative regulation of type B pancreatic cell development Regulated?
The negative regulation of type B pancreatic cell development is itself tightly regulated by multiple signaling pathways. mTOR integrates nutrient and growth factor signals to control beta cell mass and insulin secretion; its inhibition can reduce beta cell proliferation and promote apoptosis. FXR activation upregulates COX6A2, leading to mitochondrial apoptosis in beta cells. SOCS-3 is induced by cytokines and negatively regulates beta cell proliferation. FoxO1 activity is modulated by insulin/IGF signaling and oxidative stress, affecting endocrine cell formation. HIF1α stability is regulated by oxygen levels, influencing beta cell development under hypoxia. Additionally, metabolic factors such as lipid droplets and adipocyte-secreted tetranectin can negatively impact beta cell function and survival [7, 8]. These regulatory layers ensure that beta cell mass is appropriately controlled in response to physiological demands.
negative regulation of type B pancreatic cell development and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FXR/COX6A2 | Type 2 diabetes, beta cell apoptosis | Beta cell-specific knockout or overexpression in mice |
| mTOR | Type 2 diabetes, beta cell mass regulation | Inducible beta cell-specific mTOR knockout |
| SOCS-3 | Beta cell dysfunction, cytokine-induced damage | SOCS-3 knockout or transgenic mice |
| Tetranectin | Type 2 diabetes, insulin secretion defect | Tetranectin knockout mice or adipocyte-specific overexpression |
| HIF1α | Beta cell development under hypoxia | Beta cell-specific HIF1α knockout |
Type 2 diabetes
Type 2 diabetes is characterized by beta cell dysfunction and loss. FXR-regulated COX6A2 triggers mitochondrial apoptosis of beta cells, contributing to beta cell demise. mTOR dysregulation affects beta cell mass and insulin secretion, exacerbating hyperglycemia. Lipid droplet accumulation in beta cells is linked to beta cell demise in type 2 diabetes. Tetranectin, secreted by adipocytes, inhibits insulin secretion and exacerbates type 2 diabetes. These findings highlight the role of negative regulation of beta cell development in diabetes pathogenesis.
Beta cell dysfunction in metabolic syndrome
Metabolic stress, including excess pancreatic elastase, impairs acinar-beta cell communication and beta cell function. SOCS-3-mediated inhibition of beta cell proliferation may contribute to reduced beta cell mass in insulin-resistant states. HIF1α and FoxO1 also modulate beta cell development under stress conditions, linking metabolic syndrome to beta cell failure [5, 6].
Therapeutic implications
Targeting negative regulators of beta cell development could preserve or restore beta cell mass. For example, inhibiting FXR-COX6A2 signaling or modulating mTOR activity might protect beta cells from apoptosis [1, 2]. Blocking tetranectin or enhancing SOCS-3 degradation could improve insulin secretion [4, 8]. Understanding these pathways is essential for developing novel diabetes therapies.
From negative regulation of type B pancreatic cell development-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate beta cell proliferation? | CRISPR knockout of gene X in beta cell lines (e.g., INS-1, MIN6) followed by proliferation assays |
| Does a point mutation in gene Y affect beta cell apoptosis? | CRISPR point mutation knock-in in beta cells, then apoptosis assays |
| Does overexpression of gene Z inhibit beta cell differentiation? | CRISPR-mediated overexpression (e.g., CRISPRa) in progenitor cells |
| Does a tagged version of protein W localize to mitochondria during beta cell death? | Knock-in of fluorescent tag (e.g., GFP) using CRISPR |
| Does gene V regulate beta cell mass in vivo? | Beta cell-specific knockout mice generated by CRISPR |
| Does a risk variant in gene U alter beta cell function? | CRISPR knock-in of the variant in human iPSC-derived beta cells |
How to Study the negative regulation of type B pancreatic cell development Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on beta cell phenotypes | Identify negative regulators of beta cell proliferation |
| RNA-seq | Transcriptional changes | Measure COX6A2 upregulation by FXR |
| Proteomics | Protein abundance and modifications | Detect metabolic stress pathways in beta cells |
| Insulin secretion assay | Beta cell function | Assess tetranectin effect on insulin release |
| Apoptosis assay | Cell death | Evaluate FXR-COX6A2 mediated apoptosis |
| Proliferation assay | Cell division | Measure SOCS-3 inhibition of beta cell growth |
| Differentiation protocol | Beta cell lineage commitment | Study FoxO1 and HIF1α roles [5, 6] |
| Live-cell imaging | Protein localization and dynamics | Track COX6A2 mitochondrial localization |
CRISPR screening for negative regulators
Genome-wide CRISPR knockout or activation screens in beta cell lines can identify genes whose loss or overexpression affects beta cell proliferation, survival, or differentiation. These screens leverage libraries targeting all genes and select for changes in beta cell markers or viability [1, 2, 4].
Transcriptomics and proteomics
RNA-seq and proteomics can reveal changes in gene expression and protein abundance upon modulation of candidate negative regulators. For example, FXR activation alters COX6A2 expression, which can be detected by RNA-seq. Proteomic analysis of beta cells under metabolic stress can identify pathways involved in beta cell demise.
Functional assays for beta cell development
Insulin secretion assays, proliferation assays (e.g., EdU incorporation), apoptosis assays (e.g., caspase-3 activity), and differentiation protocols from iPSCs are used to measure beta cell development and function. These assays validate findings from CRISPR screens and transcriptomics [2, 5, 6, 8].
Imaging and lineage tracing
Live-cell imaging of fluorescently tagged proteins (e.g., COX6A2-GFP) and lineage tracing in mice can visualize beta cell development and negative regulation in real time. These methods provide spatial and temporal insights into beta cell fate [1, 5].
How CRISPR Can Be Used to Study GO:2000077 negative regulation of type B pancreatic cell development
Knockout
CRISPR knockout of candidate negative regulators (e.g., SOCS-3, FXR) in beta cell lines or mice can determine whether their loss enhances beta cell development or survival. For example, SOCS-3 knockout increases beta cell proliferation. FXR knockout may reduce COX6A2-mediated apoptosis.
Point Mutation
Introducing specific point mutations (e.g., in COX6A2 or mTOR) can dissect domain functions or mimic disease-associated variants. This approach helps identify critical residues for negative regulation of beta cell development [1, 2].
Knock-in
Knock-in of tags (e.g., GFP) or reporter genes allows visualization and tracking of negative regulators in beta cells. Knock-in of human disease variants into mouse models can reveal their impact on beta cell development [1, 6].
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of negative regulators (e.g., tetranectin, HIF1α) can test whether increased levels inhibit beta cell development or function. Tetranectin overexpression exacerbates diabetes in mice.
How EDITGENE Supports negative regulation of type B pancreatic cell development Research
Researchers studying negative regulation of type B pancreatic cell development-related genes often need to determine whether a candidate gene is causally involved in limiting beta cell mass or function. EDITGENE provides comprehensive CRISPR services to accelerate this discovery, from knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of type B pancreatic cell development research.
Frequently Asked Questions About negative regulation of type B pancreatic cell development
What is GO:2000077?
GO:2000077 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate or extent of pancreatic B cell (beta cell) development [1, 2].
What genes are involved in negative regulation of type B pancreatic cell development?
Key genes include FXR, COX6A2, mTOR, SOCS-3, FoxO1, HIF1α, and tetranectin, as shown in recent studies [1, 2, 4, 5, 6, 8].
How does negative regulation of beta cell development relate to diabetes?
Dysregulation of this process contributes to beta cell loss and dysfunction in type 2 diabetes [1, 2, 7, 8].
What is the role of FXR in beta cell development?
FXR regulates COX6A2, which triggers mitochondrial apoptosis of beta cells in type 2 diabetes.
How does mTOR negatively regulate beta cell development?
mTOR signaling integrates nutrient cues; its inhibition can reduce beta cell proliferation and promote apoptosis.
What is the function of SOCS-3 in beta cells?
SOCS-3 inhibits beta cell proliferation and may mediate cytokine-induced beta cell damage.
How does FoxO1 affect beta cell development?
FoxO1 regulates juxtaductal endocrine cell formation, influencing beta cell neogenesis.
What is the link between HIF1α and beta cell development?
HIF1α modulates beta cell development under hypoxic conditions.
How do lipid droplets affect beta cell survival?
Lipid droplet accumulation in beta cells is linked to beta cell demise in type 2 diabetes.
What is the role of tetranectin in diabetes?
Tetranectin, an adipocyte-secreted protein, inhibits insulin secretion and exacerbates type 2 diabetes.
Conclusion
GO:2000077, negative regulation of type B pancreatic cell development, is a critical biological process that controls beta cell mass and function. Its dysregulation is central to type 2 diabetes and metabolic disorders. Key regulators such as FXR, COX6A2, mTOR, SOCS-3, FoxO1, HIF1α, and tetranectin provide promising targets for therapeutic intervention. CRISPR-based models offer powerful tools to dissect these pathways and validate candidate genes. EDITGENE's comprehensive services can accelerate research in this field, from knockout to library screening.
References
- 1. Shao L et al.. 2024. FXR-regulated COX6A2 triggers mitochondrial apoptosis of pancreatic β-cell in type 2 diabetes.. Cell Death Dis 15(12):920 PMID: 39702527
- 2. Asahara SI et al.. 2022. Roles of mTOR in the Regulation of Pancreatic β-Cell Mass and Insulin Secretion.. Biomolecules 12(5) PMID: 35625542
- 3. Basile G et al.. 2023. Excess pancreatic elastase alters acinar-β cell communication by impairing the mechano-signaling and the PAR2 pathways.. Cell Metab 35(7):1242-1260.e9 PMID: 37339634
- 4. Lindberg K et al.. 2005. Regulation of pancreatic beta-cell mass and proliferation by SOCS-3.. J Mol Endocrinol 35(2):231-43 PMID: 16216905
- 5. Kitamura T et al.. 2009. Regulation of pancreatic juxtaductal endocrine cell formation by FoxO1.. Mol Cell Biol 29(16):4417-30 PMID: 19506018
- 6. Heinis M et al.. 2012. HIF1α and pancreatic β-cell development.. FASEB J 26(7):2734-42 PMID: 22426121
- 7. Tong X et al.. 2022. Lipid Droplets' Role in the Regulation of β-Cell Function and β-Cell Demise in Type 2 Diabetes.. Endocrinology 163(3) PMID: 35086144
- 8. Liu F et al.. 2022. The adipocyte-enriched secretory protein tetranectin exacerbates type 2 diabetes by inhibiting insulin secretion from β cells.. Sci Adv 8(38):eabq1799 PMID: 36129988
